Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GlaxoSmithKline Reaches $2.2 Billion Settlement in Zantac Lawsuits
01:50pm, Wednesday, 09'th Oct 2024
GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlement
GSK reaches up to $2.2 billion settlement in Zantac US state court cases
01:00pm, Wednesday, 09'th Oct 2024
GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion.
Here's Why GSK (GSK) is a Strong Value Stock
10:45am, Wednesday, 09'th Oct 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK Reports Sustained Efficacy of RSV Vaccine Amidst Competition from Pfizer and Moderna
11:31am, Tuesday, 08'th Oct 2024
GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjust
RSV Vaccine Demand Drops Sharply in the US, Impacting GSK's Sales
11:10am, Tuesday, 08'th Oct 2024
Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States. Major vaccine manufacturers, including GlaxoSmithKline (GSK, Financial), Mo
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
06:50am, Tuesday, 08'th Oct 2024
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people w
GSK RSV shot 43% effective against severe disease in third year
06:47am, Tuesday, 08'th Oct 2024
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
06:26am, Monday, 07'th Oct 2024
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
09:08am, Friday, 04'th Oct 2024
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.
GSK: Does RSV jab work too well?
04:48am, Tuesday, 01'st Oct 2024
GSK PLC's respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by Jefferies. The jab is designed to protect older adults
3 'Repeatable' Biotech Trades
12:46pm, Wednesday, 25'th Sep 2024
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:47am, Monday, 23'rd Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
02:01pm, Thursday, 19'th Sep 2024
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
GSK settles two California lawsuits related to heartburn drug Zantac
09:19am, Wednesday, 18'th Sep 2024
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
07:34am, Wednesday, 18'th Sep 2024
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of ag
